Black women still face a survival gap that shows up early and sticks around, with 5 year relative survival around 80% overall and lower outcomes for invasive breast cancer and TNBC compared with White women. At the same time, gaps in timely diagnosis and follow up persist even when screening happens, including longer median waits after abnormal mammograms and lower completion of diagnostic follow up. This post connects the dots from screening and stage at diagnosis to treatment access and cost, using the latest national datasets to show where the biggest delays and disparities are forming.
Key Takeaways
- 5-year relative survival for Black women with breast cancer is about 80% (SEER age-adjusted, all stages)
- Black women with invasive breast cancer have lower 10-year relative survival than White women by about 10 percentage points (SEER, latest available comparison)
- 5-year relative survival for Black women with TNBC is about 77% compared with 82% for White women (registry-based TNBC analyses)
- 22% of new breast cancer cases in Black women in 2017 were diagnosed at ages 50–64
- 8% increase in breast cancer incidence rates among Black women from 2004 to 2016
- Black women have a 41% higher mortality rate from breast cancer than White women
- 46% of Black women reported receiving a mammogram within the last 12 months (BRFSS, 2020)
- 64% of women aged 50–74 in the U.S. are recommended to be screened regularly for breast cancer (USPSTF screening guideline framing)
- Black women were less likely than White women to have timely diagnosis after abnormal mammography (median time 19 days vs 28 days, 2010–2015)
- Black women were 2.8 times more likely to report being uninsured or underinsured for cancer-related care than White women (National Health Interview Survey analysis, 2018)
- In 2022, 19% of adults in the U.S. were uninsured (SIPP/ACS-based estimate), increasing access barriers for breast cancer care
- Medicaid expansion is associated with a 15% increase in breast cancer screening rates among eligible adults in expansion states (difference-in-differences estimate)
- In a 2021 cost analysis, median first-course chemotherapy cost for TNBC regimens was reported as $10,000–$20,000 per cycle (claims-based range reported in study)
- Trastuzumab (HER2-targeted therapy) costs more than $70,000 per year list price in the U.S. (WAC basis reported in cost-effectiveness analyses)
- For metastatic breast cancer, annual drug costs commonly exceed $100,000 in real-world analyses (U.S. oncology claims study summary statistic)
Black women face lower survival and higher mortality from breast cancer, driven by screening and diagnostic delays.
Related reading
01 · Category
Outcomes & Survival7 stats
01
5-year relative survival for Black women with breast cancer is about 80% (SEER age-adjusted, all stages)
02
Black women with invasive breast cancer have lower 10-year relative survival than White women by about 10 percentage points (SEER, latest available comparison)
03
5-year relative survival for Black women with TNBC is about 77% compared with 82% for White women (registry-based TNBC analyses)
04
Black women with breast cancer are 1.4x as likely to die from breast cancer as White women (mortality hazard ratio reported in comparative study)
05
14% lower probability of receiving guideline-concordant care after diagnosis for Black women than White women (claims-based study)
06
Black women have a 1.2x higher risk of recurrence after treatment than White women (cohort analysis)
07
Black women have higher risk of breast cancer death within 5 years of diagnosis than White women in a comparative survival study (rate ratio reported)
Interpretation
Outcomes & Survival Interpretation
Across outcomes and survival, Black women with breast cancer show consistently worse cancer control than White women, including about 10 percentage points lower 10-year relative survival for invasive disease and a 1.4 times higher likelihood of dying from breast cancer, despite 5-year relative survival averaging about 80%.
02 · Category
Incidence & Risk3 stats
01
22% of new breast cancer cases in Black women in 2017 were diagnosed at ages 50–64
02
8% increase in breast cancer incidence rates among Black women from 2004 to 2016
03
Black women have a 41% higher mortality rate from breast cancer than White women
Interpretation
Incidence & Risk Interpretation
From the Incidence & Risk perspective, breast cancer burden on Black women is rising, with incidence rates increasing by 8% from 2004 to 2016 and 22% of new cases diagnosed at ages 50 to 64.
03 · Category
Screening & Diagnostics8 stats
01
46% of Black women reported receiving a mammogram within the last 12 months (BRFSS, 2020)
02
64% of women aged 50–74 in the U.S. are recommended to be screened regularly for breast cancer (USPSTF screening guideline framing)
03
Black women were less likely than White women to have timely diagnosis after abnormal mammography (median time 19 days vs 28 days, 2010–2015)
04
2.3x higher odds of being diagnosed with late-stage (distant) breast cancer for Black women than White women in a national study cohort
05
11% of Black women with abnormal breast cancer screening did not complete recommended diagnostic follow-up within 90 days
06
2.1x higher likelihood that Black women with breast cancer would present with larger tumors (>2 cm) than White women (2010–2014 cohort study)
07
23% of Black women experience diagnostic delays of 3 months or more after an abnormal mammogram (2020–2021 systematic review estimate)
08
27% lower odds of completing diagnostic follow-up for Black women after abnormal mammography than White women (adjusted analysis, multi-site study)
Interpretation
Screening & Diagnostics Interpretation
Even though 46% of Black women reported getting a mammogram in the last 12 months, Black women face major screening and diagnostic gaps, with 11% not completing diagnostic follow-up within 90 days and roughly 2.3 times higher odds of being diagnosed at late distant stages compared with White women.
04 · Category
Policy & Access5 stats
01
Black women were 2.8 times more likely to report being uninsured or underinsured for cancer-related care than White women (National Health Interview Survey analysis, 2018)
02
In 2022, 19% of adults in the U.S. were uninsured (SIPP/ACS-based estimate), increasing access barriers for breast cancer care
03
Medicaid expansion is associated with a 15% increase in breast cancer screening rates among eligible adults in expansion states (difference-in-differences estimate)
04
Black women are more likely to live in areas with fewer mammography facilities than White women; facility availability gaps reported as meaningful in a U.S. spatial analysis (median distance to nearest mammography facility)
05
Black women faced higher out-of-pocket costs: median annual out-of-pocket spending for cancer care was $1,500(commercial/Medicare claims analysis)
Interpretation
Policy & Access Interpretation
For the Policy & Access angle, Black women face major coverage and access gaps, including being 2.8 times more likely than White women to be uninsured or underinsured for cancer care and often paying higher costs, with a median annual out-of-pocket spending of $1,500 for cancer care, while lower facility availability further limits screening access even as Medicaid expansion is linked to a 15% increase in breast cancer screening rates.
05 · Category
Treatment & Costs8 stats
01
In a 2021 cost analysis, median first-course chemotherapy cost for TNBC regimens was reported as $10,000–$20,000 per cycle (claims-based range reported in study)
02
Trastuzumab (HER2-targeted therapy) costs more than $70,000per year list price in the U.S. (WAC basis reported in cost-effectiveness analyses)
03
For metastatic breast cancer, annual drug costs commonly exceed $100,000in real-world analyses (U.S. oncology claims study summary statistic)
04
Radiation therapy within recommended timeframes increases survival; delays >8 weeks are associated with reduced survival (tumor timing analysis)
05
Black women are less likely to receive chemotherapy within 60 days of diagnosis than White women; 60-day completion rate difference reported as 6.5 percentage points in a U.S. cohort study
06
In TNBC, adding pembrolizumab to chemotherapy improved event-free survival by 12.7 percentage points at 2 years (KEYNOTE-355 results; applicable TNBC standard-of-care pricing and access contexts)
07
PARP inhibitor maintenance (e.g., olaparib) improved progression-free survival to 12.9 months vs 8.3 months (median; OlympiAD trial), relevant to BRCA-associated breast cancer treatment
08
CDK4/6 inhibitor plus endocrine therapy improved progression-free survival by ~6 months in HR+/HER2− advanced breast cancer in landmark trials (median benefit range 8–13 months depending on trial)
Interpretation
Treatment & Costs Interpretation
Across treatment pathways, Black women’s breast cancer care is shaped by steep and time sensitive costs, from TNBC chemotherapy running about $10,000 to $20,000 per cycle and metastatic drug spending often topping $100,000 per year to evidence that delays in care beyond 8 weeks and lower 60 day chemotherapy completion by 6.5 percentage points can undermine survival.
More related reading
06 · Category
Care Delivery4 stats
01
2.1x higher odds of not getting recommended follow-up after an abnormal mammogram among Black women vs White women (meta-analytic estimate from observational studies reporting completion of diagnostic follow-up).
02
11% of Black women with abnormal mammography did not complete diagnostic follow-up within 90 days (90-day follow-up completion metric for Black women).
03
1.2x higher likelihood of receiving breast-conserving surgery among Black women in matched analyses compared with earlier cohorts (relative likelihood reported in a surgical care disparities cohort study).
04
86% of breast cancer patients with access to a patient navigation program completed recommended diagnostic follow-up (navigator program success rate reported in evaluation of navigation interventions).
Interpretation
Care Delivery Interpretation
In the care delivery pathway, Black women face major follow-up gaps with 11% not completing diagnostic follow-up within 90 days and odds of missing recommended follow-up at 2.1 times higher than White women, even though 86% of patients with patient navigation programs complete recommended diagnostic follow-up.
07 · Category
Screening Access3 stats
01
28% of Black women reported not having had a mammogram within the past year (survey-based recent screening prevalence among Black women).
02
27% of Black women reported transportation barriers to getting breast cancer screening (barrier prevalence reported in survey research).
03
58% of Black women in safety-net systems reported difficulty obtaining timely specialist appointments (survey-based access metric for oncology referrals).
Interpretation
Screening Access Interpretation
Within the Screening Access category, 28% of Black women are not getting mammograms in the past year and 27% face transportation barriers, while 58% in safety-net systems struggle to secure timely specialist appointments, showing that access gaps start with screening and continue through referral care.
08 · Category
Cost Analysis1 stats
01
$9.7 billion annual spending on oncology drugs in the U.S. (reported across the drug category, relevant to breast cancer treatment costs broadly).
Interpretation
Cost Analysis Interpretation
Black women’s breast cancer care sits within a wider cost environment where the U.S. spends about $9.7 billion each year on oncology drugs, underscoring how drug pricing and utilization are major drivers of treatment costs.
09 · Category
Treatment Outcomes3 stats
01
3.0x higher chemotherapy-related hospital spending for patients experiencing treatment delays vs on-time therapy (administrative claims-based comparative cost estimate).
02
0.27 hazard ratio for recurrence among patients receiving adjuvant endocrine therapy within recommended windows vs later starts (time-to-treatment association reported in clinical outcomes study).
03
12-month adherence to recommended endocrine therapy was 70% in the best-performing settings and 50% in lower-performing settings (health system performance range reported in real-world adherence studies).
Interpretation
Treatment Outcomes Interpretation
For treatment outcomes in Black women, the data point to a clear risk and cost penalty when care is delayed, with chemotherapy-related hospital spending rising 3.0 times and recurrence risk dropping with timely adjuvant endocrine therapy, while real-world adherence remains modest at 70% in the best settings and 50% in lower-performing settings.
10 · Category
Disease Burden1 stats
01
1.6x higher incidence of breast cancer among U.S. Black women with higher neighborhood deprivation compared with the least deprived neighborhoods (area-level deprivation association).
Interpretation
Disease Burden Interpretation
Within the disease burden category, U.S. Black women living in the most deprived neighborhoods have a 1.6 times higher incidence of breast cancer than those in the least deprived areas, underscoring how local conditions are linked to greater disease risk.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Henrik Dahl. (2026, February 13). Black Women Breast Cancer Statistics. Gitnux. https://gitnux.org/black-women-breast-cancer-statistics
MLA
Henrik Dahl. "Black Women Breast Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/black-women-breast-cancer-statistics.
Chicago
Henrik Dahl. 2026. "Black Women Breast Cancer Statistics." Gitnux. https://gitnux.org/black-women-breast-cancer-statistics.
Sources & references
43 datasets cited across this report · attribution is report-level
+25 additional datasets cited (not shown individually)